| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VYGR | Common Stock | Sale | -$63.7K | -9.51K | -36.17% | $6.70 | 16.8K | Jul 14, 2022 | Direct | F1, F2 |
| holding | VYGR | Common Stock | 5K | Jul 14, 2022 | See Footnote | F3 |
| Id | Content |
|---|---|
| F1 | Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on July 13, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $6.74, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
| F3 | The securities are directly held by the Pierce Family Trust, dated October 13, 1993 (the "Pierce Family Trust"). The reporting person's immediate family members are beneficiaries of the Pierce Family Trust. The reporting person expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein. |